Status:

WITHDRAWN

Sphenopalatine Ganglion Block for the Treatment of Post-Stroke Headache

Lead Sponsor:

University of Utah

Conditions:

Headache

Stroke

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Determine the effects of sphenopalatine ganglion (SPG) block in post-stroke headache.

Detailed Description

The purpose of this study is to determine if sphenopalatine ganglion (SPG) block is a safe and effective treatment for acute post-stroke headache. Current literature lacks randomized controlled studie...

Eligibility Criteria

Inclusion

  • 18 years or older;
  • hospitalization at the University of Utah Hospital with a diagnosis of acute ischemic or hemorrhagic stroke; confirmed acute post-stroke headache by treating physician;
  • meets at least one of the following International Classification of Headache Disorder-3 (ICHD-3) criteria: 6.1.1.1 (Acute Headache Attributed to Ischemic Stroke), 6.2.1 (Headache attributed to non-traumatic intracerebral hemorrhage), 6.2.2 (Acute headache attributed to non-traumatic subarachnoid hemorrhage); received at least one medication for headache during hospitalization.

Exclusion

  • Previous treatment with SPG Block for post-stroke headache
  • history of prophylactic medication use for headache or migraine;
  • pregnant at time of stroke

Key Trial Info

Start Date :

March 23 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2025

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT05365880

Start Date

March 23 2022

End Date

June 1 2025

Last Update

November 13 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Utah

Salt Lake City, Utah, United States, 84108